Shimura, Masahiko Tokyo Medical University
Kitano, Shigehiko Tokyo Women’s Medical University
Muramatsu, Daisuke Tokyo Medical University
Fukushima, Harumi Tokyo Women’s Medical University
Takamura, Yoshihiro University of Fukui
Matsumoto, Makiko Nagasaki University
Kokado, Masahide Wakayama Medical University
Kogo, Jiro St. Marianna University School of Medicine
Sasaki, Mariko Tachikawa Hospital|National Hospital Organisation Tokyo Medical Center
Morizane, Yuki Okayama University
Utsumi, Takuya Tokyo Medical University
Koto, Takashi Kyorin University
Sonoda, Shozo Kagoshima University
Hirano, Takao Shinshu University
Ishikawa, Hiroto Hyogo College of Medicine
Okamoto, Fumiki University of Tsukuba
木下, 貴正 Sapporo City General Hospital
Kimura, Kazuhiro Yamaguchi University
Sugimoto, Masahiko Mie University
Yamashiro, Kenji Japanese Red Cross Otsu Hospital
Suzuki, Yukihiko Hirosaki University
Hikichi, Taiichi Hikichi Eye Clinic
Washio, Noriaki Showa General Hospital
Sato, Tomohito National Defense Medical College
Ohkoshi, Kishiko St. Luke’s International Hospital
Tsujinaka, Hiroki Nara Medical University
Kusuhara, Sentaro Kobe University
Kondo, Mineo Mie University
Takagi, Hitoshi St. Marianna University School of Medicine
Murata, Toshinori Shinshu University
Sakamoto, Taiji Kagoshima University
To investigate the yearly change of real-world outcomes for best corrected visual acuity (BCVA) after 2-year clinical intervention for treatment-naïve diabetic macular oedema (DMO).
Retrospective analysis of aggregated, longitudinal medical records obtained from 27 retina specialised institutions in Japan from Survey of Treatment for DMO database. A total of 2049 treatment-naïve centre involving DMO eyes of which the initial intervention started between 2010 and 2015, and had been followed for 2 years, were eligible. As interventions, antivascular endothelial growth factor (VEGF) agents, local corticosteroids, macular photocoagulation and vitrectomy were defined. In each eye, baseline and final BCVA, the number of each intervention for 2 years was extracted. Each eye was classified by starting year of interventional treatment.
Although baseline BCVA did not change by year, 2-year improvement of BCVA had been increased, and reached to +6.5 letters in the latest term. There is little difference among starting year about proportions of eyes which BCVA gained >15 letters, in contrast to those which lost >15 letters were decreased by year. The proportion of eyes receiving anti-VEGF therapy was dramatically increased, while those receiving the other therapies were gradually decreased. The proportion of eyes which maintained socially good vision of BCVA>20/40 has been increased and reached to 59.0% in the latest term.
For recent years, treatment patterns for DMO have been gradually but certainly changed; as a result, better visual gain, suppression of worsened eyes and better final BCVA have been obtained. Anti-VEGF therapy has become the first-line therapy and its injection frequency has been increasing.
British Journal of Ophthalmology
BMJ Publishing Group
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
bjophthalmol_104_12_1755.pdf 817 KB